PROF Jeffrey Zajac

PROF Jeffrey Zajac


  • Adipose tissue biology (fat, obesity, metabolic syndrome, type 2 diabetes, metabolism)
  • Androgen Use in Clinical Care (androgens, testosterone, dihydrotestosterone, androgen receptor)
  • Androgen action in bone (testosterone, physiology, bone histomorphometry, osteoblasts,)
  • Androgen deprivation therapy in prostate cancer (prostate, ADT)
  • Calcitonin action in bone (calcitonin receptor, calcitonin, calcitonin-related peptides, bone cell metabolism)
  • Clincal use of Testosterone (use, misuse, abuse, androgens)
  • Genetically modified animal models in endocrinology (genetically modified animal models, transgenics, knockouts, androgen receptor, calcitonin receptor)
  • Kennedy's Disease (spinal and bulbar muscular atrophy)
  • Molecular endocrinology (androgen receptor, skeletal muscle, genetically modified mouse models, anabolic actions, androgens, testosterone)
  • Physiological role of calcitonin (calcitonin, calcitonin receptor, physiology, hypercalcaemia, calcium homeostasis)
  • Skeletal muscle biology (physiology, skeletal muscle, hypertrophy, muscle wasting)
  • Testosterone and diabetes and obesity (fat, obesity, androgens)
  • Testosterone and muscle strength (human) (muscles, androgens)
  • Teststerone and bone (osteoporosis, androgens, fractures)
  • Transgender Health (transgender, treatment)
  • Use of testosterone in clinical medicine (testosterone treatment)



  • Professor Jeffrey D Zajac
    Professor Jeffrey Zajac is Professor and Head of the University of Melbourne, Department of Medicine at Austin Health. He is a Clinical Endocrinologist and General Physician with research interests in molecular endocrinology. He is Chairman of Medicine and Director of the Department of Endocrinology at Austin Health.

    Professor Zajac trained in Medicine at the University of Melbourne and undertook a PhD in the Department of Medicine, Austin & Repatriation Medical Centre. Following postdoctoral work in the Endocrine Genetics Unit at Massachusetts General Hospital, Boston, he returned to the University of Melbourne initially at Royal Melbourne Hospital and now Austin Health. His research group has embarked on a major research program investigating the effect of androgen deprivation therapy in patients with prostate cancer. These investigations include effects on bone, muscle, cardiovascular risk and metabolic state. He also heads a molecular endocrinology group investigating the androgen receptor using genetically modified mice.

    His clinical interests include: 1) general endocrinology; 2) the use, misuse and abuse of testosterone; 3) transgenic medicine.   


Member of

  • American Society for Bone and Mineral Research. Member 1984 -
  • Australian Diabetes Society. Member 1984 -
  • Australian and New Zealand Bone and Mineral Society. Member 1984 -
  • Endocrine Society (USA). Member 1984 -
  • Endocrine Society of Australia (Past President). Member 1984 -
  • RACP. Royal Australasian College of Physicians 1984 -


Selected publications


Investigator on


Education and training

  • PhD, University of Melbourne 1985
  • MB BS, University of Melbourne 1977

Awards and honors

  • Life Member, Endocrine Society of Australia, 2015
  • Fellow of the Royal Australasian College of Physicians, 1984



Available for supervision

  • Y

Supervision Statement

  • PhD/DmedSci
    Available to supervise clinicsl endocrinolgy trainees wishing to do a higher degree in a field related to androgens, bone, muscle, diabetes or transgender health

    Available  to supervise hons student interested in clinical studies related to above topics

    Available to supervise PhD students interested to study genetically modified animal models with CRE/LOX mediated deletions of the androgen receptor. Stuides investigate effects on bone, muscle, adipose tissue and the CNS.